

Bettina Wingelhofer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/530428/publications.pdf>

Version: 2024-02-01

17
papers

614
citations

686830

13
h-index

996533

15
g-index

17
all docs

17
docs citations

17
times ranked

1302
citing authors

#	ARTICLE	IF	CITATIONS
1	STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway. <i>Oncogene</i> , 2021, 40, 1091-1105.	2.6	42
2	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	1.7	27
3	Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia. <i>Leukemia</i> , 2020, 34, 1266-1277.	3.3	24
4	STAT5 is Expressed in CD34+/CD38a~ Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	1.7	12
5	Emerging Epigenetic Therapeutic Targets in Acute Myeloid Leukemia. <i>Frontiers in Oncology</i> , 2019, 9, 850.	1.3	15
6	The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. <i>Cancer Cell</i> , 2019, 35, 125-139.e9.	7.7	43
7	Cover Image, Volume 16, Issue 1. <i>Veterinary and Comparative Oncology</i> , 2018, 16, i.	0.8	0
8	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1135-1146.	3.3	112
9	Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. <i>Leukemia</i> , 2018, 32, 1016-1022.	3.3	20
10	Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. <i>Leukemia</i> , 2018, 32, 1713-1726.	3.3	166
11	The <sc>JAK2</sc>/<sc>STAT5</sc> signaling pathway as a potential therapeutic target in canine mastocytoma. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 55-68.	0.8	19
12	Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation. <i>Molecular Cancer Research</i> , 2018, 16, 135-146.	1.5	21
13	Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 45-57.	1.5	19
14	Genome-Wide CRISPR-Cas9 Screen Identifies Sensitizers to LSD1 Inhibition in MLL-Translocated Human AML Cells. <i>Blood</i> , 2018, 132, 178-178.	0.6	0
15	O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. <i>Leukemia</i> , 2017, 31, 2132-2142.	3.3	47
16	Preloading with L-BPA, L-tyrosine and L-DOPA enhances the uptake of [18F]FBPA in human and mouse tumour cell lines. <i>Applied Radiation and Isotopes</i> , 2016, 118, 67-72.	0.7	12
17	Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. <i>Carcinogenesis</i> , 2014, 35, 2331-2338.	1.3	35